NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population (FOLLOW)
Clinical Outcomes of the NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population With Elevated Surgical Risk
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Oulu, Finland, 90220
- Oulu University Hospital
-
-
-
-
-
Bad Bevensen, Germany, 29549
- Herz- und Gefasszentrum Bad Bevensen
-
Bad Rothenfelde, Germany
- Schuechtermann-klinik
-
Hamburg, Germany, 22087
- Kath. Marienkrankenhaus
-
Hanover, Germany, 30625
- MH Hannover
-
Heilbronn, Germany, 74078
- SLK-Kliniken Heilbronn
-
-
-
-
-
Milan, Italy, 20132
- Ospedale San Raffaele
-
Naples, Italy
- Clinica Mediterranea Neapel
-
-
-
-
-
Eindhoven, Netherlands, 5623 EJ
- Heartcentre Catharina Hospital Eindhoven
-
-
-
-
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
Málaga, Spain, 29010
- Hospital Universitario Virgen de la Victoria
-
Salamanca, Spain, 37007
- Hospital Universitario De Salamanca
-
Vigo, Spain, 36213
- Hospital Alvaro Cunqueiro
-
-
-
-
-
Swansea, United Kingdom
- Morriston Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Symptomatic degeneration of severe calcified aortic heart valve OR failing surgical aortic bioprosthetic valve
- Acceptable candidate for elective treatment with the ALLEGRA TAVI System TF (according to the most recent version of the ALLEGRA Instructions For Use)
- High risk for surgery as assessed by the heart team
- Has signed the Patient Informed Consent Form >= 18 years
Exclusion Criteria:
General:
- Echocardiographic evidence of intracardiac thrombus or vegetation
- Significant aortic disease such as severe obstructive calcification or marked tortuosity or kinking which will preclude a safe advancement of the ALLEGRA TAVI System TF
- Iliofemoral vessel conditions such as severe obstructive calcification, severe tortuosity or kinking that would preclude safe placement of an 18 Fr introducer sheath or make endovascular access to the aortic valve impossible
- Severe ventricular dysfunction with LVEF <20%
- Evidence of active endocarditis or other acute infections
- Renal failure requiring continuous renal replacement therapy
- Known hypersensitivity to contrast media, which cannot be adequately pre-medicated or contraindication to anticoagulant or anti-platelet medication or to nitinol alloy or to bovine tissue
- Life expectancy ≤ 12 months due to other medical illness
- Currently participating in another investigational drug or device study
Patients with native aortic valve disease:
- Unicuspid or bicuspid aortic valve
- Non-calcified aortic stenosis
- Combined aortic valve disease with predominant aortic regurgitation > 3
- Distance between aortic valve basal plane and the orifice of the lowest coronary artery < 8 mm
Patients with degenerated surgical bioprosthetic aortic valves:
- Low position of the coronary ostia, especially in combination with shallow sinuses
- Internal diameter of the bioprosthesis is ≤16 mm or >28 mm
- Partially detached leaflets that in the aortic position may obstruct a coronary ostium
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cohort 1: Patients who undergo TAVI for symptomatic severe stenosed aortic heart valves
|
|
Cohort 2:
patients undergoing a VIV procedure in failing surgical bioprostheses.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cardiovascular death
Time Frame: 30 days post-index procedure
|
30 days post-index procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Technical success of implantation
Time Frame: day of procedure
|
Technical success of implantation, as defined by:
|
day of procedure
|
|
Safety profile according to VARC II
Time Frame: 30 days
|
Early Safety
Time-related valve safety
|
30 days
|
|
In-hospital mortality
Time Frame: date of procedure till date of estimated discharge, assessed up to two weeks
|
date of procedure till date of estimated discharge, assessed up to two weeks
|
|
|
All-cause mortality
Time Frame: up to five years
|
up to five years
|
|
|
Assesment of NYHA classification
Time Frame: 30 days, 12 month, 24 month, 36 month, 48 month, 60 month
|
30 days, 12 month, 24 month, 36 month, 48 month, 60 month
|
|
|
Quality of life (EQ5D 5L)
Time Frame: 30 days, 12 month, 24 month, 36 month, 48 month, 60 month
|
30 days, 12 month, 24 month, 36 month, 48 month, 60 month
|
|
|
New pacemaker implantation
Time Frame: up to five years
|
up to five years
|
|
|
assessment of mean aortic gradient post-implantation
Time Frame: up to five years
|
up to five years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ulrich Schäfer, MD, Herz-und Gefäßzentrum Bad Bevensen, Germany
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NVT04FOL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.